

Rev02
Update: Aug,08,2025

DATASHEET

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer, His & Avi, Human

Cat. No.: Z06614

Product Introduction

Species	Human
Protein Construction	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer[Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide] Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGACGVGK HisAvi N-termC-term
Purity	> 95% as determined by BisTris PAGE > 90% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Expression System	HEK293
Theoretical Molecular Weight	258 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background

Target Background : Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Synonyms : MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China